Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 883 clinical trials
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

A Phase1/2a Study of Rigosertib plus Nivolumab in Stage IV Lung Adenocarcinoma Patients with KRAS Mutation who Progressed on First-Line Treatment

measurable disease
cancer
small cell lung cancer
drug test
kras
  • 0 views
  • 19 Feb, 2024
  • 1 location
Cysteamine for Asthma

The purpose of this study is to see if a medicine called Cysteamine, given along with standard asthma care, will improve asthma symptoms and lung function.

prick skin
allergen
corticosteroids
eosinophil count
rhinitis
  • 14 views
  • 24 Nov, 2025
  • 1 location
First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b

Phase 1b, a study in high grade serous ovarian cancer and nonsmall cell lung cancer to evaluate the safety and clinical activity of the antibody-drug conjugate (ADC) XMT-1592.

hormonal contraception
metastasis
ovarian cancer
measurable disease
hair thinning
  • 0 views
  • 19 Feb, 2024
  • 3 locations
Driving Pressure in Neurosurgery

Center of ventilation (COV) by EIT, as well as the lung ultrasonographyLUS), perioperative ventilatory parameters, arterial oxygenation index (PaO2/FiO2) , serum indicators and postoperative pulmonary complications are secondary outcome variables.

pulmonary complications
oxygenation index
positive end expiratory pressure
neurosurgery
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers.

pd-l1
measurable disease
anaplastic lymphoma
cancer
epidermal growth factor
  • 0 views
  • 19 Feb, 2024
  • 39 locations
Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study

The main aim is to identify and describe biomarkers in different sample types related to chemoradiation followed by durvalumab treatment for stage III PD-L1 negative and positive non-small cell lung cancer (NSCLC) patients' eligible for curatively intended chemoradiation. The hypothesis is that clinical differences in course of disease reflect underlying …

pd-l1
liver metastasis
cancer
neutrophil count
pet/ct scan
  • 0 views
  • 19 Feb, 2024
  • 2 locations
Dupilumab Asthma Sleep Study

Primary Objective: To assess the effect of dupilumab on sleep Secondary Objectives: To evaluate the effect of dupilumab on additional patient reported sleep outcomes To evaluate the effect of dupilumab on objective sleep assessment To evaluate the effect of dupilumab on asthma symptoms To evaluate the effect of dupilumab on …

bronchodilator
eosinophil count
forced expiratory volume
polysomnography
fractional exhaled nitric oxide
  • 0 views
  • 24 Nov, 2025
  • 11 locations
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated Nonsquamous NSCLC

This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic disease in patients with KEAP1/NRF2-mutated, stage IV, nonsquamous, non-small cell lung cancer (NSCLC). The study primary endpoints are …

carboplatin
BRAF
measurable disease
proto-oncogene tyrosine-protein kinase ros
adjuvant
  • 0 views
  • 19 Feb, 2024
  • 28 locations
Bioequivalence and the Tolerability and Antitumor Activity of Selinexor Combination Treatment

This is a Phase 1, two-part, two-arm, open-label study in patients with NSCLC who have had 1 or 2 prior lines of treatment, with 1 line containing a CPI, or patients with CRC who have had 2 prior lines of treatment (oxaliplatin- and irinotecan-based) and no prior immunotherapy. The study …

adjuvant
liver function tests
combination therapy
small cell lung cancer
drug test
  • 0 views
  • 19 Feb, 2024
  • 3 locations
Smartphone Application for Initiation of Protective Ventilation. Clinical Impact of Instrumental Dead Space Reduction

Clinical evaluation of a new educative tools (Smartphone application) based on impact of instrumental dead space reduction after initiation of protective ventilation during mechanical ventilation.

vasopressor
mechanical ventilation
assist control
  • 0 views
  • 19 Feb, 2024
  • 1 location